glp-1 adherence Real-world persistence and to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes Revolutionizing obesity treatment: The emerging

Platelet-rich plasma has been widely investigated as a regenerative therapy in I/R injury across different organ systems

Because they dont share pathways, theres no competition for the same enzymes and therefore no direct drug-drug interaction

A meta-analysis of studies does show that people who lose more weight (e.g

T., Shah, M., & Man, C

This is particularly relevant in chronic tendinopathy, where the local repair response has stalled

With usage being so prevalent, this raises a very important question: what do these medications do to your gut, and could they increase your risk of developing microbial imbalances like SIBO, IMO, or ISO